Roche (VTX:ROG) has been assigned a CHF 300 target price by JPMorgan Chase & Co. in a report released on Thursday. The firm presently has a “buy” rating on the healthcare company’s stock. JPMorgan Chase & Co.’s price target suggests a potential upside of 19.47% from the stock’s previous close.
ROG has been the subject of a number of other reports. Goldman Sachs Group set a CHF 325 target price on Roche and gave the stock a “buy” rating in a research report on Thursday, October 12th. Morgan Stanley set a CHF 260 target price on Roche and gave the stock a “neutral” rating in a research report on Friday, November 17th. Deutsche Bank set a CHF 264 target price on Roche and gave the stock a “neutral” rating in a research report on Tuesday, December 12th. Liberum Capital set a CHF 279 target price on Roche and gave the stock a “buy” rating in a research report on Wednesday, November 22nd. Finally, Baader Bank set a CHF 231 price target on Roche and gave the stock a “neutral” rating in a report on Thursday, October 19th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of CHF 262.89.
Shares of Roche (ROG) opened at CHF 251.10 on Thursday. Roche has a 52-week low of CHF 226.10 and a 52-week high of CHF 273. The stock has a market capitalization of $216,540.00 and a price-to-earnings ratio of 22.32.
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.